^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoScan™ CNV Plus Assay

    Company:
    Thermo Fisher Scientific
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    1year
    Utility of Retrospective Molecular Analysis in Diagnostically Challenging Mesenchymal Neoplasms. (PubMed, Int J Surg Pathol)
    "Molecular testing helped reach a definitive diagnosis in 50% of tumors (n = 5/10). Although the overall utility of this approach is limited, these molecular panels can be helpful in detecting a specific "driver" alteration."
    Journal • Retrospective data
    |
    OncoScan™ CNV Plus Assay • TruSight Tumor 170 Assay
    over2years
    [VIRTUAL] Diagnostic and Clinical Utility of OncoScan CNV Plus Assay Testing in Pediatric Solid Tumors (AMP 2021)
    The validation studies and clinical cases analyzed have established OS+ as a reliable test for detection of CNAs, cnLOH, and SMs in FFPE neoplasms. The availability, cost, turn-around time, and comprehensiveness are factors that make OS+ a principal test for pediatric solid tumor analysis at our institution.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    BRAF V600E • BRAF V600 • NRAS G13 • KRAS deletion
    |
    OncoScan™ CNV Plus Assay
    over2years
    Molecular Characterization Using Oncoscan Chromosome Microarray in an International Cohort of 51 Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (ASH 2021)
    However, widespread genomic alterations were detected involving a variety of cancer-associated genes further characterizing CNA in BPDCN. Analysis of additional BPDCN cases is progress.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CD19 (CD19 Molecule) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • PTEN mutation • PIK3CA mutation + PTEN mutation
    |
    OncoScan™ CNV Plus Assay
    over3years
    Clinical Validation of Somatic Mutation Detection by the Oncoscan CNV Plus Assay. (PubMed, J Mol Diagn)
    "The conclusion is that a majority of HC OS+ SM calls were accurate, except calls identified in EGFR and PTEN. Clinically, this laboratory reports SM identified by OS+ only after Sanger sequencing verification."
    Journal • Clinical
    |
    EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog)
    |
    OncoScan™ CNV Plus Assay